✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025

Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin have announced that full data from the pivotal KOMET-001 trial of their investigational menin inhibitor, ziftomenib, will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Ziftomenib, a once-daily oral therapy, is the first investigational drug to receive Breakthrough Therapy Designation from the FDA for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML), a mutation present in about 30% of AML cases with no approved targeted therapies.

A doctor examining a patient’s x-ray in a laboratory, showing the capabilities of the company’s oncology therapies.

The KOMET-001 trial achieved its primary endpoint, demonstrating statistically significant rates of complete remission and partial hematological recovery. Ziftomenib also showed a favorable safety profile, with limited myelosuppression and only 3% of patients discontinuing due to side effects. Kura Oncology, Inc.’s CEO, Dr. Troy Wilson, emphasized the drug’s potential as a new treatment option for this difficult-to-treat AML subgroup and reaffirmed the company’s commitment to advancing ziftomenib toward commercialization.

Additionally, a poster on the ongoing KOMET-015 trial will be presented at ASCO. Detailed data and session information are now available on the ASCO website, with further results to be revealed at the meeting.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.